Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities

Canadian Journal of Psychiatry

Volumn 46, Issue 3, 2001, Pages 273-281

  McIntyre, Roger S ^a   McCann, Sonia M ^b   Kennedy, Sidney H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Atypical antipsychotics; Conventional antipsychotics; Diabetes mellitus; Obesity; Obesity comorbidity; Triglyceride; Weight gain

Indexed keywords

CHOLESTEROL; CLOZAPINE; GLUCOSE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

AGE; APPETITE; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; DIABETES MELLITUS; DISEASE DURATION; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; MEDICAL INFORMATION; OBESITY; PATIENT MONITORING; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035004541     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370104600308     Document Type: Article

References (111)

1. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence report
2. World Health Organization: Preventing and managing the global epidemic
3. Recent advances in basic obesity research
4. The spread of the obesity epidemic in the United States, 1991-1998
5. Body weight and mortality among women
6. Weight changes during treatment with phenothiazine derivatives
7. Weight changes with schizophrenic psychosis and psychotropic drug therapy
8. Conventional versus novel antipsychotics: Changing concepts and clinical implications
9. A growing problem in schizophrenia management: Weight gain. Physician Perspective Viewpoint
10. The distribution of body mass index among individuals with and without schizophrenia
11. Smoking and therapeutic response to clozapine in patients with schizophrenia
12. The effect of antipsychotic drugs on body weight: A retrospective review
13. Weight changes with depot neuroleptic maintenance therapy
14. Weight gain associated with antipsychotic drugs
15. Weight gain among schizophrenic patients treated with clozapine
16. Clozapine-induced weight gain: Prevalence and clinical significance
17. Clozapine and weight gain
18. Differential effect of clozapine on weight: A controlled study
19. Weight gain induced by clozapine
20. Antipsychotic-induced weight gain a comprehensive research synthesis
21. Molindone in chronic schizophrenia
22. Molindone: A crossover evaluation of capsule and tablet formulations in severely ill schizophrenia
23. Weight reduction in schizophrenics by molindone
24. Novel antipsychotics comparison of weight gain liabilities
25. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
26. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder
27. Antipsychotic agents and bipolar disorder
28. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder
29. Clozapine in bipolar disorder treatment implications for other atypical antipsychotics
30. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months
31. Factors associated with weight gain during olanzapine treatment
32. Too many chronic mentally disabled patients are too fat
33. Beiträge zum Verlauf des Körpergewichts bei Psychosen
34. Weight changes in relation to the characteristics of patients on chlorpromazine
35. Weight gain: Side effect of atypical neuroleptics?
36. Safety profile of risperidone
37. Safety of olanzapine
38. Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders
39. Weight gain associated with neuroleptic medication: A review
40. Lithium revisited: Current status, future prospects
41. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid
42. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy
43. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine Hl and alpha l-adrenergic receptors in vitro
44. 2 dopamine receptors involved?
45. Hypothalamic sites affecting masticatory neurons in rats
46. Sulpride injections in the lateral hypothalamus induce feeding and drinking in rats
47. Systemic sulpride increases dopamine metabolites in the lateral hypothalamus
48. 2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DO1)
49. Eating disorder and epilepsy in mice lacking 5-HT-sub(2C) serotonin receptors
50. Reduction of food intake by manipulation of central serotonin: Current experimental results
51. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity
52. m-Clorophenylpiperazine decreases food intake in a test meal
53. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
54. Pharmacological and neurochemical studies with the new antipsychotic ziprasidone
55. Management of psychotropic drug-induced obesity
56. The relationship between prolactin levels and risk of breast cancer in premenopausal women
57. Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs
58. Metabolic fuels and reproduction in female mammals
59. Insulin binding and action on adipocytes from female rats with experimentally induced chronic hyperprolactinemia
60. Neuroleptic-induced hyperprolactinemia
61. Recombinant mouse ob protein. Evidence for a peripheral signal linking adiposity and central neural networks
62. Effects of gender, body composition, and menopause on plasma concentrations of leptin
63. Congenital leptin deficiency is associated with severe early-onset: Obesity in humans
64. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
65. Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration
66. Recombinant leptin for wight loss in obese and lean adults
67. Serum leptin levels increase rapidly after initiation of clozapine therapy
68. Body weight and leptin plasma levels during treatment with antipsychotic drugs
69. Prevalence of attempting weight loss and strategies for controlling weight
70. Psychotomimetic effects of anorectic drngs
71. Psychotic mania associated with fenfluramine and phenteremine use
72. Nonpharmacologic and pharmacologic management of weight gain
73. Topiramate: Preclinical evaluation of a structurally novel anticonvulsant
74. Use of topiramate, a new anti-leptic as a mood stabilizer
75. Topiramate in severe treatment-refractory mania
76. A pilot of adjunctive topiramate in the treatment of bipolar disorder
77. Treatment of bipolar depression with topiramate: A new anticonvulsant drug
78. Mood stabilization and weight loss with topiramate
79. Topiramate augmentation: A preliminary open study of its effectiveness in women with refractory rapid cycling bipolar disorder and significant weight gain from previous treatment
80. Topiramate in the treatment of refractory bipolar mood disorder
81. Topiramate as add-on treatment for patients with bipolar mania
82. Topiramate versus bupropion SR added to mood stabilizer therapy for the depressive phase of bipolar disorder: A single blind study
83. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control
84. 1998 clinical practice guidelines for the management of diabetes in Canada
85. Severe hyperglycemia associated with high doses of clozapine
86. Diabetic ketoacidosis associated with clozapine treatment
87. Ketoacidosis as a side-effect of clozapine: A case report
88. Lactic ketoacidosis and fatal myocardial failure due to clozapine
89. Diabetic ketoacidosis from clozapine and lithium cotreatment
90. Clozapine and associated diabetes mellitus
91. Novel antipsychotics and new onset diabetes
92. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
93. Olanzapine-induced ketoacidosis with diabetes mellitus
94. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
95. Risperidone treatment for a patient suffering from schizophrenia and IDDM
96. Risperidone and glucose intolerance
97. Antipsychotics linked to weight gain, diabetes
98. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin, and glucagon in the rat
99. Acute pancreatitis associated with clozapine use
100. Clozapine-related pancreatitis
101. Serotonin receptor subtypes: Possible roles and implications in antipsychotic drug action
102. The involvement of the peripheral 5-HT2A receptor in peripherally administered serotonin-induced hyperglycemia in rats
103. Different influences of classic antipsychotics and clozapine on the glucose-insulin homeostasis in patients with schizophrenia or related psychosis
104. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities a five-year naturalistic study
105. The increase of plasma levels of triglyceride during clozapine treatment: A case report
106. Serum triglyceride levels in patients treated with clozapine
107. Clozapine-associated elevation in serum triglycerides
108. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study
109. Olanzapine increases weight and serum triglyceride levels
110. Olanzapine-induced elevation of plasma triglyceride levels